Evolus (NASDAQ:EOLS) Stock Price Expected to Rise, Barclays Analyst Says

Evolus (NASDAQ:EOLS) had its price target raised by analysts at Barclays from $20.00 to $22.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 54.60% from the stock’s previous close.

Several other analysts also recently weighed in on EOLS. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Wednesday, January 22nd.

Evolus Stock Up 1.5 %

EOLS stock opened at $14.23 on Monday. The company’s 50 day moving average is $11.79 and its two-hundred day moving average is $13.81. Evolus has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $901.04 million, a P/E ratio of -15.64 and a beta of 1.32.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of EOLS. KBC Group NV purchased a new position in shares of Evolus during the 4th quarter valued at approximately $49,000. Quarry LP acquired a new position in Evolus during the 2nd quarter worth $54,000. Point72 Asset Management L.P. bought a new stake in shares of Evolus in the 3rd quarter worth about $132,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Evolus in the 3rd quarter valued at about $191,000. Finally, Profund Advisors LLC bought a new position in shares of Evolus during the second quarter worth about $130,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.